Tuhura Biosciences Inc

This management proposal seeks shareholder approval under Nasdaq Listing Rule 5635(d) for the issuance of 1,878,287 shares to Parkview Holdings One LLC as the commitment fee for a $50 million secured revolving credit facility entered on April 21, 2026. Management asserts Nasdaq may aggregate this issuance with prior securities issued to an affiliate, K&V Investment, in a December 2025 registered direct offering such that the combined issuance could exceed Nasdaq’s 20% threshold and thus requires stockholder approval. The Board argues approval preserves cash by avoiding a $5.0 million cash fee, secures critical financing to fund clinical trials and operations into early 2028, and enhances the company’s financial flexibility without resorting to more dilutive or expensive financing alternatives. The Loan Agreement and Fee Letter include additional terms — an annual facility fee, royalty payments on IFx-2.0 net sales, extension of certain warrant exercise periods, and customary covenants and events of default — which create long-term obligations and potential dilution via conversion upon a Change of Control. The proposal presents governance considerations because Parkview and K&V Investment are affiliated and Parkview may obtain the right to appoint a director, raising potential related-party influence concerns; Nasdaq aggregation and affiliate status make board self-dealing and independence issues relevant. The Board justifies the transaction as negotiated at arm’s length and in the company’s and stockholders’ best interests given the immediate liquidity needs and runway benefits, but approval will dilute existing holders and could affect future voting power and market metrics. Analysts evaluating this transaction should weigh the trade-off between near-term liquidity and dilution, the financial covenants and royalty burden on future product revenue, the identity and incentives of Parkview/K&V (including their large pre-existing holdings), and the potential governance impact of a significant affiliated lender obtaining board access. The Board’s unanimous recommendation and the explicit cash-avoidance rationale strengthen management’s case; however, the affiliated-party nature of the transaction and the royalty obligations warrant scrutiny as to long-term cost and alignment with stockholder value creation.

This non-binding management proposal asks shareholders to approve the company’s disclosed named executive officer compensation (a ‘‘say-on-pay’’ vote). Management argues that its compensation framework—base salary, annual incentives, and equity awards governed by established plans and committee oversight—aligns executive incentives with long-term stockholder value, motivates performance, and aids retention. The Compensation Committee will consider the advisory vote results when evaluating future pay decisions, so while the vote is not binding, an adverse outcome could prompt management engagement with large holders and adjustments to program design or disclosure. Key context includes sizeable option and bonus arrangements for the CEO and CFO, employment agreements with severance and change-of-control protections, and the company’s status as a clinical-stage biopharma requiring management continuity to execute development plans. The vote should be viewed in light of pay-versus-performance disclosures, the recent merger activity (Kintara Merger), and year-to-year changes in equity grant practices; significant opposition could signal misalignment or governance concerns. For sophisticated evaluation, consider relative size of realized vs. reported compensation (CAP), the structure and potential dilution of equity awards, clawback and recoupment policies, and whether compensation milestones tie to measurable clinical/regulatory or commercial outcomes. Given the Board’s unanimous recommendation, management is emphasizing stability and continuity; however, investors should assess whether incentive design and governance safeguards sufficiently protect long-term shareholder interests.

This management-sponsored, non-binding proposal asks shareholders to indicate their preferred frequency for future advisory say-on-pay votes—one, two, or three years—with the Board endorsing a three-year cycle. Management’s rationale is that a triennial frequency gives investors and the company sufficient time to observe the effects of compensation policies on long-term performance, reduces administrative burden, and avoids reactionary adjustments to longer-term incentive programs. The company states its compensation program does not change significantly year-to-year and that three years provides a more complete period to evaluate the mix and magnitude of pay in relation to strategic milestones. From a governance perspective, more frequent votes (annual) offer more responsive shareholder feedback, while less frequent votes reduce short-termism but also dilute shareholder engagement cadence. For investors and analysts, the relevant considerations include the company’s development timeline (clinical milestones and regulatory events), historical responsiveness to past say-on-pay outcomes, and whether a three-year cadence might delay corrective action if major pay misalignments arise. Although non-binding, a strong shareholder vote against management’s recommended frequency could trigger engagement and potential policy adjustments; conversely, strong support would endorse management’s view on longer-term assessment periods. Evaluators should weigh the trade-offs between accountability and strategic consistency in the context of a clinical-stage biotech with multi-year development horizons.

This management proposal seeks stockholder authorization to permit the holder of any proxy solicited by the Board to vote in favor of adjourning or postponing the Annual Meeting to allow additional time to solicit proxies if there are insufficient votes to approve Proposal 2 (the Nasdaq Proposal) or to constitute a quorum. The company explains that, if necessary, the meeting could be adjourned without notice for up to 30 days (so long as no new record date is set) and reconvened to transact any business that could have been transacted at the original meeting. Strategically, this proposal protects the Board’s ability to pursue necessary financing approvals by enabling supplemental solicitation when a close vote or insufficient participation threatens approval of the Parkview issuance. While common and generally uncontroversial, the adjournment authority can be used to extend solicitation pressure on dissenting holders and change the dynamics of contested votes, which raises governance and fairness considerations for large stockholders. Investors should note this is conditional—adjournment would be used to seek approval of a transaction the Board supports (Proposal 2)—and assess whether repeated adjournments could be used to overwhelm opposition. The Board’s unanimous recommendation underscores its desire to ensure the Nasdaq Proposal gets a fair opportunity for approval, but shareholders should consider whether sufficient transparency and engagement occurred prior to the meeting to merit such contingency powers.